Zobrazeno 1 - 10
of 577
pro vyhledávání: '"MJ Ellis"'
Autor:
Mark F. Watson, Jeremy Hoog, Abigail S. Caudle, Erika C. Crouch, Y. Wang, Lisa A. Carey, Mitchell Dowsett, AH Partridge, Kiran Vij, Wajeeha Razaq, Cynthia X. Ma, Anna Weiss, Tina J. Hieken, T Dockter, Amy Tiersten, EP Winer, J. M. Guenther, VJ Suman, H. Maluf, A. M. Leitch, Olwen Hahn, JoAnne Zujewski, Gary Unzeitig, Monica M. Mita, MJ Ellis, Clifford A. Hudis, K. K. Hunt, S Sanati
Publikováno v:
Cancer Research. 81:PD2-10
Background: NET is offered to postmenopausal patients (pts) with clinical stage 2/3 ER+/HER2- BC to promote breast-conserving surgery. Also limited surgical accessibility during the COVID19 pandemic has increased NET utility. Inability to identify ET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f154ece5b9908354e73679927881ed3
https://doi.org/10.1158/1538-7445.sabcs20-pd2-10
https://doi.org/10.1158/1538-7445.sabcs20-pd2-10
Autor:
MJ Ellis
Publikováno v:
Cancer Research. 80:TS1-3
Improvements in breast cancer treatment are being achieved at an increasing pace in all three clinical subsets of the disease, namely ER+ HER2- (luminal), HER2+ (HER2-driven) and ER- PgR- and HER2- (triple negative). While these disease groupings ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ec3cf7899d69dacf3641fc1fa5d35ea
https://doi.org/10.1158/1538-7445.sabcs19-ts1-3
https://doi.org/10.1158/1538-7445.sabcs19-ts1-3
Autor:
J Newby, A Hutton, SA Mertz, K De La Torre, T Pollastro, MJ Ellis, L Campbell, Hurlbert, NM Iyengar, CE Williams
Publikováno v:
Cancer Research. 79:P6-15
Metastatic breast cancer (MBC) remains an incurable disease and is the cause of nearly all deaths from breast cancer. Several barriers prevent efficient research into various questions about living with MBC. A key unmet need is a national database fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e64aaceaba7121056c148206de43be0
https://doi.org/10.1158/1538-7445.sabcs18-p6-15-03
https://doi.org/10.1158/1538-7445.sabcs18-p6-15-03
Autor:
E Sahin, Purba Singh, M Leng, B-J Kim, MJ Ellis, Airi Han, Jonathan T. Lei, Ryoichi Matsunuma, Chun-Yang Fan, Anna Malovannaya, Chonghui Cheng, Alexander B. Saltzman, CM Perou, Doug W. Chan
Publikováno v:
Cancer Research. 79:P5-08
Proteogenomics is the field of integrating data from mass spectrometry-based shotgun proteomics, and phosphoproteomics into next-generation RNA and DNA sequencing data analysis pipelines that promises new insights into cancer biology and therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d1f1e5947b19547252312647090f101
https://doi.org/10.1158/1538-7445.sabcs18-p5-08-01
https://doi.org/10.1158/1538-7445.sabcs18-p5-08-01
Autor:
SM Kavuri, V Devarakonda, LC Williams, S Seker, JT Lei, P Singh, A Han, M Anurag, KR Holloway, AL Welm, MJ Ellis
Publikováno v:
Cancer Research. 79:P6-17
Background Until recently, HER2 gene amplification was the only mechanism of HER2 activation recognized. However, activating HER2 mutations have been noted in different cancer types. A trials of HER2 mutant breast cancer and the subsequent SUMMIT tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b19e132ce5044068b76f9013b2b65ac9
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-15
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-15
Autor:
Jeffrey S. Abrams, GW Sledge, CE Geyer, T. Lively, VG Kaklamani, JL Berenberg, MP Goetz, JA Olson, Joseph A. Sparano, DL Toppmeyer, M. Keane, Timothy F. Goggins, Kathy S. Albain, S Paik, DF Hayes, Robert Gray, KI Pritchard, T.J. Saphner, Timothy J. Whelan, LI Wagner, Pavan S. Reddy, Peter M. Ravdin, MJ Ellis, Sunil Badve, AM Brufsky, Henry L. Gomez, William C. Wood, IA Mayer, DF Makower, EC Dees
Publikováno v:
Cancer Research. 79:GS4-07
Background: Black race is associated with worse outcomes in localized hormone receptor (HR)-positive breast cancer in population-based and in clinical trial cohorts, whether using self-identified race (Albain et al. JNCI 2009 [PMID: 19584328; Sparano
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5088d7b70d9a938e86b8e93482324c0
https://doi.org/10.1158/1538-7445.sabcs18-gs4-07
https://doi.org/10.1158/1538-7445.sabcs18-gs4-07
Publikováno v:
Cancer Research. 79:P1-06
Background: Alterations to mismatched repair (MMR) pathways are a known cause of cancer (particularly colorectal and endometrial). Recently, the FDA approved pembrolizumab for use in MMR-deficient (MMRD) cancers of any type, and the diagnosis can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b65aec9092ff3111c0567d6d932a866d
https://doi.org/10.1158/1538-7445.sabcs18-p1-06-02
https://doi.org/10.1158/1538-7445.sabcs18-p1-06-02
Autor:
Ashley Frith, Ron Bose, Tracy Summa, MJ Ellis, Foluso O. Ademuyiwa, Katherine N. Weilbaecher, Leonel Hernandez-Aya, Mathew Cherian, Ina Chen, F Guo, Lindsay L. Peterson, Rama Suresh, Michael Naughton, Cynthia X. Ma, William E. Gillanders, Jianyang Luo
Publikováno v:
Cancer Research. 79:P1-15
Background: Platinum-based chemotherapy is still considered investigational for the treatment of sporadic triple negative breast cancer (TNBC). Since patients with TNBC have a high rate of chemotherapy resistance, it is critical to identify platinum-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ff063a1a791ec19f249d930abb496ac
https://doi.org/10.1158/1538-7445.sabcs18-p1-15-05
https://doi.org/10.1158/1538-7445.sabcs18-p1-15-05
Publikováno v:
Cancer Research. 78:P4-12
Introduction: Breast cancer is the most common cancer in women worldwide, and 70% of breast cancer deaths occur in women from low-income and middle-income countries. In Brazil there were 14388 deaths due to this disease in 2013 and an estimate of ove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dd95a775d962c7aa5736d1a0aa53f33
https://doi.org/10.1158/1538-7445.sabcs17-p4-12-04
https://doi.org/10.1158/1538-7445.sabcs17-p4-12-04
Publikováno v:
Cancer Research. 78:P2-09
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors improve disease free survival for patients (pts) with advanced hormone receptor positive (HR+) and HER2 negative (HER2-) breast cancer (BC). However, there are no established biomarkers that id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e68f791fad01ef113ad0123b64446db4
https://doi.org/10.1158/1538-7445.sabcs17-p2-09-16
https://doi.org/10.1158/1538-7445.sabcs17-p2-09-16